Posted by Michael Wonder on 09 Dec 2016
Biogen and AbbVie receive Health Canada approval of once monthly Zinbryta (daclizumab beta) for multiple sclerosis
9 December 2016 - Approval supported by largest and longest head-to-head global Phase 3 study conducted in multiple sclerosis.
Health Canada has approved Zinbryta (daclizumab beta), a new once-monthly, self-administered, subcutaneous treatment for adult patients with active relapsing remitting multiple sclerosis, who have had an inadequate response to, or are unable to tolerate, one or more therapies indicated for the treatment of multiple sclerosis, Biogen and AbbVie announced today.
The Health Canada approval of Zinbryta is based on results from two clinical trials, including DECIDE, the largest and longest head-to-head global Phase 3 clinical trial conducted in multiple sclerosis. The Phase 2b SELECT and Phase 3 DECIDE studies were global, randomised, double-blind, controlled studies that involved approximately 2,400 people living with relapsing MS. Some patients in DECIDE were treated for up to three years.
